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Introduction
Previous studies have revealed elevated levels of matrix
metalloproteinase-2 (MMP-2) in atherosclerotic plaques of
coronary arteries and in plasma after the onset of acute my-
ocardial infarction (AMI) (Kai et al. 1998). An MMP-2 sin-
gle nucleotide polymorphism, -1306T>C, displayed strik-
ingly high promoter activity of the C allele (Price et al.
2001). The present study analysed whether or not the MMP-
2 -1306T>C polymorphism contributed to the development
of AMI in a Mexican population. An increased probabil-
ity of AMI associated with the MMP-2 CC genotype was
found. AMI risk associated with the CC genotype was more
pronounced in obese or hypertensive individuals. The data
suggest that MMP-2 -1306T>C polymorphism contributes to
AMI development in the population studied.
Myocardial infarction is the major cause of death by dis-
ease in the world (Ciruzzi et al. 2003). The most important
risk factors for AMI are hypercholesterolemia, high blood
pressure, diabetes, obesity, smoking and family history of
coronary heart disease. Atherosclerosis of the coronary ar-
teries is the predominant AMI mechanism. Atherosclerotic
plaque growth occurs through structural changes which al-
low the accumulation of cells, extracellular matrix and lipids
in the intimate layer of the diseased artery. The rupture or
erosion of the fibrous layer of the atheromatous plaque gives
rise to thrombosis, which is the factor setting oﬀ, a chain
of events leading to AMI (Newby 2005; Tedgui and Mallat
2006).
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AMI physiopathology is complex at the molecular level
and involves a wide variety of proteins, including the ma-
trix metalloproteinases (MMPs). Experiments suggest that
MMP action can facilitate the formation of atheromatous
plaque (Tedgui and Mallat 2006). Additionally, some MMPs
(MMP-2, MMP-3 and MMP-9) specifically attack type IV
collagen, laminin and fibronectin, which are the major com-
ponents of the basal lamina around blood vessels (Newby
2005). There is evidence that the action of MMP enzymes
weakens the arterial wall, contributing to the destabilizing
and rupture of atheromatous plaque, leading to AMI (Newby
2005; Tedgui and Mallat 2006).
Elevated MMP-2 levels have been detected in the plasma
of patients with angina pectoris (Kai et al. 1998). Over-
expressed MMP-2 has also been found directly in atheroscle-
rotic plaques of coronary arteries (Pasterkamp et al. 2000).
MMP-2 blood levels were shown to increase gradually after
the onset of AMI, with maximum elevation on day 21 af-
ter onset (Hojo et al. 2001). High levels of MMP-1, MMP
-9, and MMP-13 have also been detected in post-infarction
phases (Hlatky et al. 2007; Suzuki et al. 2008). These obser-
vations show the association of MMPs with physiopatholog-
ical processes of AMI.
MMP expression can vary among individuals due to ge-
netic diﬀerences, which could influence susceptibility to vas-
cular disease. At present, there are only a few polymor-
phisms within the MMP genes that are clearly associated
with AMI (MMP-3 -1171 5A/6A, MMP-9 -1562C/T and
279R/Q) (Abilleira et al. 2006). However, studies on MMP
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genetic variations in AMI are scarce. Price et al. (2001) iden-
tified the -1306T>C polymorphism of the MMP-2 promoter.
This base transition is located in the CCACC box of the Sp1-
binding site. The -1306CC genotype causes elevated enzy-
matic MMP-2 expression and activity, and could be an AMI
risk factor. The present case–control study analyses the as-
sociation between the MMP-2 -1306C>T polymorphism and
the development of AMI in a population in western Mexico.
Materials and methods
Study population
Written informed consent was obtained from all the subjects
who participated in this study, and the study protocol was
approved by the institutional review board of the School of
Medicine of the University of Colima and the IMSS Hospital
General (HG) N◦1. The study conformed to the principles of
the World Medical Association’s Declaration of Helsinki.
Between January 2006 and May 2007, a total of 98 AMI
patients (case group) were recruited from a public health
system hospital (HG N◦1 of the IMSS) in the city of Col-
ima, Mexico. The control group comprised of 163 non-
hospitalized individuals with no medical history of ischemic
vascular disease (corroborated clinically and by electrocar-
diography), who were seen in family medicine consultations
in the same public hospital at the same point of time. The cri-
teria for selecting subjects for the control group were same
sex and similar age (not more than five-years diﬀerence)
as patients in the case group (1–2 control subjects per one
case subject). The control group subjects had come to the
hospital for routine check-ups, preventive or early diagnosis
and treatment measures for diabetes, high blood pressure or
some acute ailment not requiring hospitalization. Individuals
suﬀering from autoimmune, thyroid, neoplastic, or hepatic
(such as cirrhosis) diseases or presenting with chronic infec-
tions were excluded from this study. All study participants
were non-blood-related Mexican mestizo subjects from the
state of Colima, Mexico. A case history was elaborated for
each participant through interviews and data obtained from
oﬃcial medical records.
Definitions
AMI diagnosis was made by a cardiologist based on World
Health Organization (WHO) criteria. Arterial hypertension
was considered to be present if the patient had a history of
high blood pressure or presented with blood pressure val-
ues above 140/90 mm Hg one week after the event. High
blood pressure was also considered present in patients re-
ceiving antihypertensive medication (Hsieh et al. 2005). Di-
abetes mellitus was considered to be present when fasting
blood glucose concentrations were over 1260 mg/L or if a
history of diabetes was reported (including patients receiving
diabetes medication). Hyperlipidemia was defined as fasting
total serum cholesterol over 2000 mg/L or triglycerides over
2000 mg/L, and was considered to be present in all patients
receiving lipid-lowering medications. Smoking was defined
as the smoking of 100 or more cigarettes during the patient’s
lifetime (Medina-Mora et al. 2002). An individual was con-
sidered to be overweight or obese if body mass index was
over 25 and 30, respectively.
Polymorphism analysis
Peripheral venous blood (2 mL) was drawn from partic-
ipants and stored in EDTA tubes for no longer than a
week at 4◦C until DNA extraction was carried out (phenol-
chloroform extraction and DNA precipitation with abso-
lute ethanol). MMP-2 polymorphism was studied by the
PCR-RFLP method, as previously described (Gonzalez-
Hernandez et al. 2008).
Statistical analysis
Evaluation of Hardy–Weinberg equilibrium was performed
by comparing observed and expected genotypes, using chi-
square analysis. Chi-square test (the Fisher exact test) was
used to examine diﬀerences between cases and controls when
two nominal variables were compared, and the Student t-test
was used to compare the mean values of the measurement
variables (age or BMI, both normally distributed) The asso-
ciation between the MMP-2 polymorphism and risk of AMI
was estimated by odds-ratios (OR) and 95% confidence in-
tervals (c.i.) (Crosstabs procedure), which were calculated
controlling others risk factors using a Mantel–Haenszel anal-
ysis. All statistical analyses were performed with SPSS ver-
sion 11.0 software (SPSS, Chicago, USA).
Results
The principal clinical characteristics, such as genotype fre-
quency, are shown in table 1. Of all the clinical character-
istics, hyperlipidemia was the only one in which there was
a significant diﬀerence between cases and controls. MMP-2
-1306C allele frequency was 0.78 and 0.82, for the control
and case groups, respectively (P = 0.18). The distribution
of MMP-2 genotypes in the control group (table 1) was in
Hardy–Weinberg equilibrium (P = 0.65). Since TT geno-
type was rare (4.3% of the case group and 8.2% of the control
group), it was combined with the CT genotype as the variant
group for subsequent analysis.
Because the proportion of hyperlipidemia was diﬀerent
between case and control groups, all OR analyses were car-
ried out controlling for that variable. The adjusted OR
for subjects carrying the CC genotype was 2.05 (95% c.i.:
1.09−3.85, P = 0.02) for AMI. Eﬀects of the CC genotype
were additionally examined in subgroups of individuals with
high blood pressure, diabetes and obesity (table 2). The dis-
tribution of MMP-2 genotypes in the control subgroups (high
blood pressure, diabetic or obese patients) were in Hardy–
Weinberg equilibrium. It was found that increased proba-
bility of AMI associated with the MMP-2 CC genotype was
more pronounced in obese or hypertensive subjects.
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Table 1. Distribution of selected characteristics by
case–control status.
Control Case
Variables n = 163(%) n = 98(%) P
Age (years) 61.4 ± 9.2 61.7 ± 9.9 0.63
Sex
Female 66 (40.5) 35 (35.7) 0.51
Male 97 (59.5) 63 (64.3)
Smoking 82 (50.3) 57 (58.2) 0.25
Diabetes 2 69 (42.3) 43 (43.9) 0.89
Hypertension 102 (62.6) 61 (62.2) 1.00
Dislypidemia 25 (15.3) 62 (63.3) 0.00∗
BMI, kg/m2 28.2 ± 4.4 28.9 ± 4.7 0.55
Obesity 46 (28.2) 34 (34.7) 0.33
Genotype
TT 7 (4.3) 8 (8.2) 0.27
CT 60 (36.8) 19 (19.4) 0.00∗
CC 96 (58.9) 71 (72.4) 0.04∗
*Significant diﬀerence.
Table 2. Odds ratio (OR) for eﬀects of MMP-2 -1306 polymor-
phism on acute myocardial infarction in hypertensive, diabetic and
obese patients.
Genotype (n) Adjusted OR**
Sample CT/TT/CC (c.i. 95%) P
Control 66* 97 2.05 (1.09 − 3.85) 0.025
Case 27 71
Hypertensive subjects
Control 43* 59 3.03 (1.25 − 7.32) 0.014
Case 16 45
Diabetic subjects
Control 26* 43 2.28 (0.84 − 6.18) 0.103
Case 12 31
Obesity subjects
Control 21* 25 3.59 (1.20 − 10.74) 0.022
Case 6 28
*Reference; **adjusted for hyperlipidemia.
Discussion
Results from the present study showed that the MMP-2 -
1306 CC genotype increased AMI risk (OR 2) in the pop-
ulation studied. Previously, Vasku et al. (2004) had found
that a haplotype made up of four MMP-2 promoter poly-
morphisms (-1575G, -1306C, -790T and -735C) was asso-
ciated with coronary triple-vessel disease. Although Vasku
et al. (2004) found no direct association between the MMP-2
-1306 polymorphism and cardiac ischemia, a haplotype con-
taining the -1306C allele was found to be associated with
the disease. This is congruent with our results. However, it
is important to mention that our study and that of Vasku et
al. (2004) were carried out on populations of diﬀerent eth-
nic origins and that not all the patients analysed by Vasku et
al. (2004) presented with AMI. This could explain why the
MMP-2 -1306 polymorphism, itself, was not associated with
ischemic cardiopathy (coronary triple-vessel disease) in the
study of Vasku et al. (2004).
In a recent study by Horne et al. (2007), on diﬀerent
MMP polymorphisms in AMI, various MMP-1/MMP-3 and
MMP-9 genotypes were associated with the disease. How-
ever, MMP-2 -1306 polymorphism genotypes were not as-
sociated with the development of AMI, unlike in our study.
This could be due to the diﬀerent ethnic origins of the re-
spective study populations. Ninety per cent of the individu-
als analysed by Horne et al. (2007) were from a Caucasian
population of the United States, while our study included
only a western Mexican mestizo population. Although there
can be discrepancies at a genetic level as to the importance
of the role of MMP-2 polymorphisms as AMI risk factors,
the fact that MMP-2 intervene in the processes that trigger
and /or signal AMI evolution has clearly been demonstrated
(Pasterkamp et al. 2000; Hojo et al. 2001; Newby 2005;
Tedgui and Mallat 2006).
There is an elevation of MMP-2 levels in diﬀerent
stages of AMI physiopathology. This enzyme is elevated in
atherosclerotic plaques of coronary arteries (Pasterkamp et
al. 2000) as well as in plasma after the onset of AMI (Hojo
et al. 2001). Additionally, mice with cardiac-specific trans-
genic expression of active MMP-2 have a larger infarction
size compared to wild-type hearts (Zhou et al. 2007). MMP-
2 -1306CC genotype increases MMP-2 expression in vitro
and this increase could be related to AMI through two pro-
cesses: (i) by facilitating leukocyte and lipoprotein infiltra-
tion into the endothelium, which is necessary for the devel-
opment of atherosclerosis, and (ii) by weakening the arterial
wall, which can destabilize and break atheromatous plaque,
leading to AMI (Newby 2005; Tedgui and Mallat 2006).
It was also observed that the presence of the CC genotype
in hypertensive or obese patients increased AMI risk more
than three-fold. In diabetic patients, the OR for the genotype
remained stable and did not demonstrate statistically signif-
icant changes. Chronically hypertensive patients have pre-
sented with an increase of MMP-2 expression and activation
(Yasmin et al. 2005), while obese patients have presented
with an elevation of leptin (an endocrine hormone) which en-
hances MMP-2 expression in coronary vascular cells (Park
et al. 2001). It is probable that MMP-2 elevation by the
-1306CC genotype becomes more relevant and represents
more AMI risk when another factor that increases the en-
zyme is present, as occurs in obese or hypertensive patients.
Similar results were found for ischemic stroke: a clear as-
sociation between -1306CC genotype and IS was detected,
but only in hypertensive patients (Gonzalez-Hernandez et al.
2008).
The MMP-2 -1306CC genotype acts as an AMI risk fac-
tor in more than half of the patients studied. MMP inhibition
has already been proposed for the treatment of cardiovascu-
lar disease (Peterson 2006). The results of the present study
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lend support to the idea that MMP-2 inhibition could become
a therapeutic target for AMI prevention, at least in the popu-
lation studied.
An important characteristic of the present study was
that AMI diagnosis was carried out based on WHO crite-
ria, which does not detect very small infarcts, unlike the cri-
teria recommended by the European Society of Cardiology
and the American College of Cardiology (Alpert et al. 2000).
This must be taken into account when comparing the present
study with similar studies.
The present study showed that the MMP-2 -1306CC
genotype increased the risk of developing acute myocardial
infarction. More such studies on diﬀerent populations need
to be carried out.
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